GKM-001: Phase Ib/IIa data

An Indian Phase Ib/IIa trial in 60 Type II diabetics showed that once-daily doses of 25, 50, 200, 600 and 1,000 mg GKM-001 for 14 days were well tolerated and dose-dependently reduced glucose levels f...